Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – ...

These five large-cap value dividend stocks look poised to provide some second-half gains with steady ultra-high-yield ...

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

Pfizer (PFE) recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for ...

Let's see why these funds could be worth holding onto for the long term. The post 5 high-quality ASX ETFs to buy and hold for ...

Arvinas Holding Company recently held its earnings call, revealing a balanced sentiment among stakeholders. The company showcased strong clinical progress and significant collaborations, notably with ...